Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma
The addition of cetuximab (CTX) to the combination of cisplatin and 5-fluorouracil increases the overall survival (OS) in recurrent/metastatic head and neck squamous cell carcinoma. Only a few patients are eligible for this treatment because of its toxicity. The combination of CTX and paclitaxel (TX...
Gespeichert in:
| Veröffentlicht in: | Anti-cancer drugs 2012-10, Vol.23 (9), p.996-1001 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1001 |
|---|---|
| container_issue | 9 |
| container_start_page | 996 |
| container_title | Anti-cancer drugs |
| container_volume | 23 |
| creator | Péron, Julien Ceruse, Philippe Lavergne, Emilie Buiret, Guillaume Pham, Bich-Nga Chabaud, Sylvie Favier, Bertrand Girodet, Didier Zrounba, Philippe Ramade, Antoine Fayette, Jérôme |
| description | The addition of cetuximab (CTX) to the combination of cisplatin and 5-fluorouracil increases the overall survival (OS) in recurrent/metastatic head and neck squamous cell carcinoma. Only a few patients are eligible for this treatment because of its toxicity. The combination of CTX and paclitaxel (TXL) could be included in sequential treatment strategies. Patients were treated with CTX (400/250 mg/m) and TXL (60–80 mg/m) weekly until disease progression or unacceptable toxicity. Efficacy and safety outcomes were determined retrospectively. A total of 42 patients were included in this analysis. The overall response rate was 38% [95% confidence interval (CI); 23–53%]. The disease control rate with TXL and CTX combination was 74%. Seven (17%) patients progressed before the first evaluation. The median progression-free survival was 3.9 months [95% CI; 3.1–4.7 months] and the median OS was 7.6 months [95% CI; 5.3–9.9 months]. Neurotoxicity and skin rash were the most frequent grade≥2 toxicities, reported in 17 and 12% of patients, respectively. Previous chemotherapy seems to be associated with a lower response rate and progression-free survival but not with the OS. The combination of CTX and TXL was an active and well-tolerated treatment in this series of patients with a poor prognosis and who were mostly symptomatic. |
| doi_str_mv | 10.1097/CAD.0b013e32835507e5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_proquest_miscellaneous_1113221959</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1113221959</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4895-18c3d0be546927ddabcae139ae7751fe866d9d77068a4fbe654701f8a5285e853</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi0EokvhDRDyEQ5p7diOneNqoS3SSnCAszVxJlpTJ9naDu2-DY-Kly09cOA00uibf2b-n5C3nF1w1urLzfrjBesYFyhqI5RiGtUzsuJSi0ppyZ-TFWtVW8lWizPyKqUfjLHSFy_JWV03UjBpVuTXV3DBZ3jAQGHqqcO8PPgROurmsfMTZD9PFIfBO4-TO1AYMkaad0gH8GGJSOeBAt2HQk7LWHWQsMjscJwLFGF_oH6iEd0SI075csQMKRfY0R1C_2fphO6WprsFxnlJ5YQQqIPo_DSP8Jq8GCAkfPNYz8n3q0_fNjfV9sv15816WzlpWlVx40TPOlSyaWvd99A5QC5aQK0VH9A0Td_2WrPGgBw6bJTUjA8GVG0UGiXOyYeT7g6C3cdiQTzYGby9WW_tscfq2tRaqZ-8sO9P7D7OdwumbEefjmfDhOUDyzkXdc2L-wWVJ9TFOaWIw5M2Z_aYoy052n9zLGPvHjcs3Yj909Df4ApgTsD9HEog6TYs9xhtsTTk3f-1fwOoya4c</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1113221959</pqid></control><display><type>article</type><title>Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Péron, Julien ; Ceruse, Philippe ; Lavergne, Emilie ; Buiret, Guillaume ; Pham, Bich-Nga ; Chabaud, Sylvie ; Favier, Bertrand ; Girodet, Didier ; Zrounba, Philippe ; Ramade, Antoine ; Fayette, Jérôme</creator><creatorcontrib>Péron, Julien ; Ceruse, Philippe ; Lavergne, Emilie ; Buiret, Guillaume ; Pham, Bich-Nga ; Chabaud, Sylvie ; Favier, Bertrand ; Girodet, Didier ; Zrounba, Philippe ; Ramade, Antoine ; Fayette, Jérôme</creatorcontrib><description>The addition of cetuximab (CTX) to the combination of cisplatin and 5-fluorouracil increases the overall survival (OS) in recurrent/metastatic head and neck squamous cell carcinoma. Only a few patients are eligible for this treatment because of its toxicity. The combination of CTX and paclitaxel (TXL) could be included in sequential treatment strategies. Patients were treated with CTX (400/250 mg/m) and TXL (60–80 mg/m) weekly until disease progression or unacceptable toxicity. Efficacy and safety outcomes were determined retrospectively. A total of 42 patients were included in this analysis. The overall response rate was 38% [95% confidence interval (CI); 23–53%]. The disease control rate with TXL and CTX combination was 74%. Seven (17%) patients progressed before the first evaluation. The median progression-free survival was 3.9 months [95% CI; 3.1–4.7 months] and the median OS was 7.6 months [95% CI; 5.3–9.9 months]. Neurotoxicity and skin rash were the most frequent grade≥2 toxicities, reported in 17 and 12% of patients, respectively. Previous chemotherapy seems to be associated with a lower response rate and progression-free survival but not with the OS. The combination of CTX and TXL was an active and well-tolerated treatment in this series of patients with a poor prognosis and who were mostly symptomatic.</description><identifier>ISSN: 0959-4973</identifier><identifier>EISSN: 1473-5741</identifier><identifier>DOI: 10.1097/CAD.0b013e32835507e5</identifier><identifier>PMID: 22643048</identifier><language>eng</language><publisher>England: Lippincott Williams & Wilkins, Inc</publisher><subject>Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - pathology ; Cetuximab ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Cisplatin - therapeutic use ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - mortality ; Head and Neck Neoplasms - pathology ; Humans ; Indexing in process ; Kaplan-Meier Estimate ; Life Sciences ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - prevention & control ; Paclitaxel - administration & dosage ; Paclitaxel - adverse effects ; Paclitaxel - therapeutic use ; Retrospective Studies ; Treatment Failure</subject><ispartof>Anti-cancer drugs, 2012-10, Vol.23 (9), p.996-1001</ispartof><rights>2012 Lippincott Williams & Wilkins, Inc.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4895-18c3d0be546927ddabcae139ae7751fe866d9d77068a4fbe654701f8a5285e853</citedby><cites>FETCH-LOGICAL-c4895-18c3d0be546927ddabcae139ae7751fe866d9d77068a4fbe654701f8a5285e853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22643048$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://univ-lyon1.hal.science/hal-02282755$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Péron, Julien</creatorcontrib><creatorcontrib>Ceruse, Philippe</creatorcontrib><creatorcontrib>Lavergne, Emilie</creatorcontrib><creatorcontrib>Buiret, Guillaume</creatorcontrib><creatorcontrib>Pham, Bich-Nga</creatorcontrib><creatorcontrib>Chabaud, Sylvie</creatorcontrib><creatorcontrib>Favier, Bertrand</creatorcontrib><creatorcontrib>Girodet, Didier</creatorcontrib><creatorcontrib>Zrounba, Philippe</creatorcontrib><creatorcontrib>Ramade, Antoine</creatorcontrib><creatorcontrib>Fayette, Jérôme</creatorcontrib><title>Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma</title><title>Anti-cancer drugs</title><addtitle>Anticancer Drugs</addtitle><description>The addition of cetuximab (CTX) to the combination of cisplatin and 5-fluorouracil increases the overall survival (OS) in recurrent/metastatic head and neck squamous cell carcinoma. Only a few patients are eligible for this treatment because of its toxicity. The combination of CTX and paclitaxel (TXL) could be included in sequential treatment strategies. Patients were treated with CTX (400/250 mg/m) and TXL (60–80 mg/m) weekly until disease progression or unacceptable toxicity. Efficacy and safety outcomes were determined retrospectively. A total of 42 patients were included in this analysis. The overall response rate was 38% [95% confidence interval (CI); 23–53%]. The disease control rate with TXL and CTX combination was 74%. Seven (17%) patients progressed before the first evaluation. The median progression-free survival was 3.9 months [95% CI; 3.1–4.7 months] and the median OS was 7.6 months [95% CI; 5.3–9.9 months]. Neurotoxicity and skin rash were the most frequent grade≥2 toxicities, reported in 17 and 12% of patients, respectively. Previous chemotherapy seems to be associated with a lower response rate and progression-free survival but not with the OS. The combination of CTX and TXL was an active and well-tolerated treatment in this series of patients with a poor prognosis and who were mostly symptomatic.</description><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Cetuximab</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Cisplatin - therapeutic use</subject><subject>Disease-Free Survival</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - mortality</subject><subject>Head and Neck Neoplasms - pathology</subject><subject>Humans</subject><subject>Indexing in process</subject><subject>Kaplan-Meier Estimate</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - prevention & control</subject><subject>Paclitaxel - administration & dosage</subject><subject>Paclitaxel - adverse effects</subject><subject>Paclitaxel - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Treatment Failure</subject><issn>0959-4973</issn><issn>1473-5741</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQhi0EokvhDRDyEQ5p7diOneNqoS3SSnCAszVxJlpTJ9naDu2-DY-Kly09cOA00uibf2b-n5C3nF1w1urLzfrjBesYFyhqI5RiGtUzsuJSi0ppyZ-TFWtVW8lWizPyKqUfjLHSFy_JWV03UjBpVuTXV3DBZ3jAQGHqqcO8PPgROurmsfMTZD9PFIfBO4-TO1AYMkaad0gH8GGJSOeBAt2HQk7LWHWQsMjscJwLFGF_oH6iEd0SI075csQMKRfY0R1C_2fphO6WprsFxnlJ5YQQqIPo_DSP8Jq8GCAkfPNYz8n3q0_fNjfV9sv15816WzlpWlVx40TPOlSyaWvd99A5QC5aQK0VH9A0Td_2WrPGgBw6bJTUjA8GVG0UGiXOyYeT7g6C3cdiQTzYGby9WW_tscfq2tRaqZ-8sO9P7D7OdwumbEefjmfDhOUDyzkXdc2L-wWVJ9TFOaWIw5M2Z_aYoy052n9zLGPvHjcs3Yj909Df4ApgTsD9HEog6TYs9xhtsTTk3f-1fwOoya4c</recordid><startdate>201210</startdate><enddate>201210</enddate><creator>Péron, Julien</creator><creator>Ceruse, Philippe</creator><creator>Lavergne, Emilie</creator><creator>Buiret, Guillaume</creator><creator>Pham, Bich-Nga</creator><creator>Chabaud, Sylvie</creator><creator>Favier, Bertrand</creator><creator>Girodet, Didier</creator><creator>Zrounba, Philippe</creator><creator>Ramade, Antoine</creator><creator>Fayette, Jérôme</creator><general>Lippincott Williams & Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>1XC</scope></search><sort><creationdate>201210</creationdate><title>Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma</title><author>Péron, Julien ; Ceruse, Philippe ; Lavergne, Emilie ; Buiret, Guillaume ; Pham, Bich-Nga ; Chabaud, Sylvie ; Favier, Bertrand ; Girodet, Didier ; Zrounba, Philippe ; Ramade, Antoine ; Fayette, Jérôme</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4895-18c3d0be546927ddabcae139ae7751fe866d9d77068a4fbe654701f8a5285e853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Cetuximab</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Cisplatin - therapeutic use</topic><topic>Disease-Free Survival</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - mortality</topic><topic>Head and Neck Neoplasms - pathology</topic><topic>Humans</topic><topic>Indexing in process</topic><topic>Kaplan-Meier Estimate</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - prevention & control</topic><topic>Paclitaxel - administration & dosage</topic><topic>Paclitaxel - adverse effects</topic><topic>Paclitaxel - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Treatment Failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Péron, Julien</creatorcontrib><creatorcontrib>Ceruse, Philippe</creatorcontrib><creatorcontrib>Lavergne, Emilie</creatorcontrib><creatorcontrib>Buiret, Guillaume</creatorcontrib><creatorcontrib>Pham, Bich-Nga</creatorcontrib><creatorcontrib>Chabaud, Sylvie</creatorcontrib><creatorcontrib>Favier, Bertrand</creatorcontrib><creatorcontrib>Girodet, Didier</creatorcontrib><creatorcontrib>Zrounba, Philippe</creatorcontrib><creatorcontrib>Ramade, Antoine</creatorcontrib><creatorcontrib>Fayette, Jérôme</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Anti-cancer drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Péron, Julien</au><au>Ceruse, Philippe</au><au>Lavergne, Emilie</au><au>Buiret, Guillaume</au><au>Pham, Bich-Nga</au><au>Chabaud, Sylvie</au><au>Favier, Bertrand</au><au>Girodet, Didier</au><au>Zrounba, Philippe</au><au>Ramade, Antoine</au><au>Fayette, Jérôme</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma</atitle><jtitle>Anti-cancer drugs</jtitle><addtitle>Anticancer Drugs</addtitle><date>2012-10</date><risdate>2012</risdate><volume>23</volume><issue>9</issue><spage>996</spage><epage>1001</epage><pages>996-1001</pages><issn>0959-4973</issn><eissn>1473-5741</eissn><abstract>The addition of cetuximab (CTX) to the combination of cisplatin and 5-fluorouracil increases the overall survival (OS) in recurrent/metastatic head and neck squamous cell carcinoma. Only a few patients are eligible for this treatment because of its toxicity. The combination of CTX and paclitaxel (TXL) could be included in sequential treatment strategies. Patients were treated with CTX (400/250 mg/m) and TXL (60–80 mg/m) weekly until disease progression or unacceptable toxicity. Efficacy and safety outcomes were determined retrospectively. A total of 42 patients were included in this analysis. The overall response rate was 38% [95% confidence interval (CI); 23–53%]. The disease control rate with TXL and CTX combination was 74%. Seven (17%) patients progressed before the first evaluation. The median progression-free survival was 3.9 months [95% CI; 3.1–4.7 months] and the median OS was 7.6 months [95% CI; 5.3–9.9 months]. Neurotoxicity and skin rash were the most frequent grade≥2 toxicities, reported in 17 and 12% of patients, respectively. Previous chemotherapy seems to be associated with a lower response rate and progression-free survival but not with the OS. The combination of CTX and TXL was an active and well-tolerated treatment in this series of patients with a poor prognosis and who were mostly symptomatic.</abstract><cop>England</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>22643048</pmid><doi>10.1097/CAD.0b013e32835507e5</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-4973 |
| ispartof | Anti-cancer drugs, 2012-10, Vol.23 (9), p.996-1001 |
| issn | 0959-4973 1473-5741 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1113221959 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - pathology Cetuximab Cisplatin - administration & dosage Cisplatin - adverse effects Cisplatin - therapeutic use Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Female Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - mortality Head and Neck Neoplasms - pathology Humans Indexing in process Kaplan-Meier Estimate Life Sciences Male Middle Aged Neoplasm Metastasis Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - prevention & control Paclitaxel - administration & dosage Paclitaxel - adverse effects Paclitaxel - therapeutic use Retrospective Studies Treatment Failure |
| title | Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A00%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Paclitaxel%20and%20cetuximab%20combination%20efficiency%20after%20the%20failure%20of%20a%20platinum-based%20chemotherapy%20in%20recurrent/metastatic%20head%20and%20neck%20squamous%20cell%20carcinoma&rft.jtitle=Anti-cancer%20drugs&rft.au=P%C3%A9ron,%20Julien&rft.date=2012-10&rft.volume=23&rft.issue=9&rft.spage=996&rft.epage=1001&rft.pages=996-1001&rft.issn=0959-4973&rft.eissn=1473-5741&rft_id=info:doi/10.1097/CAD.0b013e32835507e5&rft_dat=%3Cproquest_hal_p%3E1113221959%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1113221959&rft_id=info:pmid/22643048&rfr_iscdi=true |